01/24/23 8:00 AMNasdaq : FNCH clinical trialFinch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other AssetsFinch Therapeutics Group, Inc. (the “Company,” “Finch,” or “Finch Therapeutics”) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing theRHEA-AIneutral
11/10/22 7:00 AMNasdaq : FNCH earningsFinch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial ResultsFinch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), aRHEA-AIneutral
11/09/22 8:00 AMNasdaq : FNCH conferencesFinch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx ConferenceFinch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,RHEA-AIneutral
10/24/22 8:00 AMNasdaq : FNCH clinical trialFinch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile InfectionFinch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,RHEA-AIneutral
09/01/22 8:00 AMNasdaq : FNCH Finch Therapeutics Provides Business UpdateFinch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,RHEA-AIneutral
08/25/22 4:30 PMNasdaq : FNCH Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBDFinch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,RHEA-AIneutral
08/11/22 7:00 AMNasdaq : FNCH earningsFinch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial ResultsOn track to proceed with enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI in H2 2022 On track to submit IND for FIN-211 in children with autism and significant GI symptoms in Q4 2022 Additional results from PRISM-EXT Phase 2 trial of CP101 in recurrent CDI accepted for presentation atRHEA-AIneutral
06/02/22 7:00 AMNasdaq : FNCH conferencesFinch Therapeutics to Participate in Upcoming June Investor ConferencesFinch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,RHEA-AIneutral
05/17/22 8:00 AMNasdaq : FNCH conferencesFinch Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceFinch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,RHEA-AIneutral
05/16/22 7:00 AMNasdaq : FNCH earningsFinch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsFDA lifted clinical hold on IND for CP101 Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022 $15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024 Corporate update call today at 8am ET SOMERVILLE, Mass., May 16, 2022RHEA-AIneutral